May 8, 2025, 21:44

ACPMP Changemaker Research Grant: $150K for Innovation in Appendix Cancer and PMP Research

The Appendix Cancer Pseudomyxoma Peritonei Research Foundation (ACPMP) is accepting applications for its Changemaker Research Grant, offering $150,000 over two years to support groundbreaking research in the diagnosis, treatment, and cure of appendix cancer and pseudomyxoma peritonei (PMP).

Who is eligible?

Applicants must:

Be the principal investigator with primary responsibility for the project
Be affiliated with an institution capable of administering grant funds
Be able to launch the project within the 2-year grant term
Agree to ACPMP’s terms regarding stewardship, reporting, and ethical research conduct
Not accept conflicting funding that would require relinquishment of this award

Funding at a glance:

150,000 USD total
- 75,000 USD disbursed upon award acceptance
- 75,000 USD released after a satisfactory 12-month progress report
Funds must support direct research expenses only
Indirect costs, administrative charges, and non-research-related expenses are not allowed

Research focus:

Projects must align with ACPMP’s mission to advance understanding and treatment of appendix cancer and PMP, including:

Therapeutic development
Biomarker discovery
Novel diagnostics
Clinical trial infrastructure or readiness

Key obligations & reporting:

Submit interim reports at 6 and 12 months
Submit final reports within 60 days of grant conclusion
Ongoing annual progress updates required for 3 years post-grant
Public dissemination of non-confidential results encouraged
All publications must acknowledge ACPMP support

How to apply:

Visit www.acpmp.org for the Request for Proposals and application process. Applications are reviewed by ACPMP’s scientific leadership and grantmaking panel.

Contact:

Email: [email protected]

ACPMP Appendix Cancer biomarker research cancer Cancer diagnostics cancer grant funding Changemaker Grant clinical trials OncoDaily Oncology PMP research Pseudomyxoma peritonei rare cancer Translational Oncology

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research